LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Search

KemPharm Inc

Closed

0

Overview

Share price change

24h

Current

Min

Max

Key metrics

By Trading Economics

Income

33M

-3.1M

Sales

8.4M

20M

EPS

-0.06

Profit margin

-15.19

Employees

59

EBITDA

11M

-5.4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+160.51% upside

Dividends

By Dow Jones

Next Earnings

12 sie 2025

Market Stats

By TradingEconomics

Market Cap

62M

487M

Previous open

0

Previous close

0

KemPharm Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lut 2025, 15:29 UTC

Acquisitions, Mergers, Takeovers

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million

5 sie 2024, 11:25 UTC

Major Market Movers

Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol

Peer Comparison

Price change

KemPharm Inc Forecast

Price Target

By TipRanks

160.51% upside

12 Months Forecast

Average 22.43 USD  160.51%

High 25 USD

Low 19 USD

Based on 8 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$